Navigate Fool.com
Will BIOS beat
the market?

BioScrip, Inc.


Community Rating: 3 Stars: Appealing

7.47 0.27 (3.75%)

REAL-TIME: Last trade at

Extended Hours: $7.47 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.27
Previous Close $7.20
Daily Range $7.06 - $7.47
52-Week Range $5.61 - $17.62
Market Cap $509.4M
P/E Ratio -8.67
Dividend (Yield) $0.00 (0.0%)
Volume 1,758,754
Average Daily Volume 1,631,270
Current FY EPS $0.06

How do you think BIOS
will perform against the market?

Top BIOS Bull/Bear Pitches


cbierbaum (< 20)
Submitted November 5, 2009

BIOS has begun to cut necessary overhead reaching critical mass and positive operating leverage. According to an analysis conducted by Kaiser Permanente most payors contract with more than one specia … More

0 Replies Reply Report this Post

printpuppy (0)
Submitted January 17, 2007

Sales force is gone, CAP (medicare) program is disaster (company is only provider only because no one else wanted it), management has put golden parachutes in place.

0 Replies Reply Report this Post

News & Commentary Rss Feed

Why BioScrip Inc. Shares Stumbled

BioScrip shares dip despite the company delivering strong revenue growth in the fourth quarter. Should investors buy this dip or is there more than meets the eye to this earnings report?

Will Bad News in New York and Tokyo Sink Novartis AG (ADR)?

Over the past two days, Novartis has been sued by the New York Attorney General’s office and slapped with criminal charges in Tokyo. Will this double whammy of bad news sink the company, and will its industry peers BioScrip, Merck, GlaxoSmithKline, and Biogen be affected?

CVS Caremark's Big Thanksgiving Purchase: The Coram Buyout

The oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.

Why BioScrip, Frontline, and Prosensa Are Today's 3 Best Stocks

A monstrous amount of economic data sends the S&P 500 to a new all-time high. Find out why BioScrip, Frontline, and Prosensa hurtled their way to the head of the pack.

Why BioScrip Inc. Shares Soared by Association

BioScrip shares ride the coattails of a competitor to big gains. Is this the turnaround shareholders have been waiting for, or could this rally fade?

BIOS, INWK, LAYN - Mario Gabelli Update

Why BioScrip Shares Tanked

Is this meaningful? Or just another movement?

Retail Pharmacies: Why Margins Could Decrease

What is the outlook for Rite Aid, CVS, and BioScrip?

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against BioS

Infusing a Fragmented Market

Consolidating the home infusion market continues to offer mixed results for investors due to margin concerns.

See More BIOS News...





BioScrip, Inc. (BIOS) Description

The Company provides pharmaceutical and pharmacy benefit management services. Website: http://www.bioscrip.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks